PUBLISHER: DelveInsight | PRODUCT CODE: 2082714
PUBLISHER: DelveInsight | PRODUCT CODE: 2082714
ESR1 Mutated Metastatic Breast Cancer - Epidemiology Forecast - 2036
ESR1-mutated Metastatic Breast Cancer Insights and Trends
- The total number of diagnosed prevalent cases of HR positive breast cancer in the 7MM was nearly 1.3 million in 2025.
- According to SEER statistics, at the time of diagnosis, approximately 63% of breast cancer patients have local-stage breast cancer, 29% have the regional stage, and 6% have the distant (metastatic) disease, while 2% remain in an unknown stage.
- Estrogen receptor alpha (ERa), encoded by the ESR1 gene, is a member of the nuclear hormone receptor superfamily expressed in ~70% of newly diagnosed breast cancers.
- ESR1 mutations rarely exist in primary tumors ~ 1% but are relatively common 10-50% in metastatic, endocrine therapy-resistant cancers and are associated with a shorter progression-free survival.
DelveInsight's 'ESR1-mutated Metastatic Breast Cancer - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the ESR1-mutated metastatic breast cancer, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
ESR1-mutated Metastatic Breast Cancer Understanding and Diagnosis Algorithm
ESR1-mutated Metastatic Breast Cancer Overview and Diagnosis
ESR1-mutated metastatic breast cancer is a subtype of hormone receptor-positive (HR+), HER2-negative breast cancer in which mutations occur in the estrogen receptor gene (ESR1). These mutations typically develop during or after prolonged exposure to endocrine therapies, especially aromatase inhibitors. The mutation causes the estrogen receptor to become constitutively active, meaning it can signal cancer cell growth even in the absence of estrogen. As a result, the disease becomes more aggressive and resistant to standard hormone-based treatments, leading to progression in the metastatic setting.
ESR1-mutated Metastatic Breast Cancer Diagnosis
The diagnosis of ESR1-mutated metastatic breast cancer is mainly performed using molecular testing techniques. The most common approach is a liquid biopsy, where circulating tumor DNA (ctDNA) is analyzed from a blood sample to detect ESR1 mutations non-invasively. Alternatively, tissue biopsy followed by next-generation sequencing (NGS) can also identify these mutations. Testing is usually recommended when there is disease progression during or after endocrine therapy, as identifying ESR1 mutations helps guide treatment decisions and switch to more effective targeted therapies.
ESR1-mutated Metastatic Breast Cancer Epidemiology
Key Findings from ESR1-mutated Metastatic Breast Cancer Epidemiological Analysis and Forecast
- The total number of prevalent cases of breast cancer in the US was nearly 1.14 million in 2025.
- In 2025, among EU4 and the UK, Germany had the highest cases of ESR1-mutated HR positive metastatic breast cancer.
- Localized stage-specific prevalence is more than regional stage-specific in ESR1 breast cancer.
Scope of the Report:
- The report covers a segment of a descriptive overview of ESR1-mutated metastatic breast cancer, explaining their causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
ESR1-mutated Metastatic Breast Cancer Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of ESR1-mutated metastatic breast cancer? What will be the growth opportunities across the 7MM concerning the patient population with ESR1-mutated metastatic breast cancer?
- What is the historical and forecasted ESR1-mutated metastatic breast cancer patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology Methodology of ESR1-mutated Metastatic Breast Cancer
5. ESR1-mutated Metastatic Breast Cancer Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background And Overview of ESR1-mutated Metastatic Breast Cancer
- 6.1. Introduction
- 6.2. Causes
- 6.3. Signs And Symptoms
- 6.4. Diagnosis
- 6.4.1. Differential Diagnosis
- 6.4.2. Diagnostic Algorithm
- 6.4.3. Diagnostic Guidelines
7. Epidemiology and Patient Population of ESR1-mutated Metastatic Breast Cancer
- 7.1. Key Findings
- 7.2. Assumption and Rationale
- 7.3. Total Prevalent Cases of ESR1-mutated Metastatic Breast Cancer in the 7MM
- 7.4. The United States
- 7.4.1. Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in the United States
- 7.4.2. Stage-specific Diagnosed Prevalent Cases of HR Positive Breast Cancer in the United States
- 7.4.3. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in the United States
- 7.4.4. Diagnosed Prevalent Cases of ESR1-mutated Metastatic Breast Cancer in the United States
- 7.4.5. Line-wise Treatable Cases of ESR1-mutated Metastatic Breast Cancer in the United States
- 7.5. EU4 and the UK
- 7.5.1. Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in EU4 and the UK
- 7.5.2. Stage-specific Diagnosed Prevalent Cases of HR Positive Breast Cancer in EU4 and the UK
- 7.5.3. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in EU4 and the UK
- 7.5.4. Diagnosed Prevalent Cases of ESR1-mutated Metastatic Breast Cancer in EU4 and the UK
- 7.5.5. Line-wise Treatable Cases of ESR1-mutated Metastatic Breast Cancer in EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Diagnosed Prevalent Cases of HR Positive Breast Cancer in Japan
- 7.6.2. Stage-specific Diagnosed Prevalent Cases of HR Positive Breast Cancer in Japan
- 7.6.3. Total Diagnosed Prevalent Cases of Metastatic Breast Cancer in Japan
- 7.6.4. Diagnosed Prevalent Cases of ESR1-mutated Metastatic Breast Cancer in Japan
- 7.6.5. Line-wise Treatable Cases of ESR1-mutated Metastatic Breast Cancer in Japan
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables
- Table 1: ESR1 Mutated Metastatic Breast Cancer Epidemiology in 7MM (2022-2036)
- Table 2: ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in 7MM (2022-2036)
- Table 3: ESR1 Mutated Metastatic Breast Cancer Epidemiology in the United States (2022-2036)
- Table 4: ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in the United States (2022-2036)
- Table 5: ESR1 Mutated Metastatic Breast Cancer Epidemiology in Germany (2022-2036)
- Table 6: ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in Germany (2022-2036)
- Table 7: ESR1 Mutated Metastatic Breast Cancer Epidemiology in France (2022-2036)
- Table 8: ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in France (2022-2036)
- Table 9: ESR1 Mutated Metastatic Breast Cancer Epidemiology in Italy (2022-2036)
- Table 10: ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in Italy (2022-2036)
- Table 11: ESR1 Mutated Metastatic Breast Cancer Epidemiology in Spain (2022-2036)
- Table 12: ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in Spain (2022-2036)
- Table 13: ESR1 Mutated Metastatic Breast Cancer Epidemiology in the United Kingdom (2022-2036)
- Table 14: ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in the United Kingdom (2022-2036)
- Table 15: ESR1 Mutated Metastatic Breast Cancer Epidemiology in Japan (2022-2036)
- Table 16: ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in Japan (2022-2036)
List of Figures
- Figure 1 ESR1 Mutated Metastatic Breast Cancer Epidemiology in 7MM (2022-2036)
- Figure 2 ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in 7MM (2022-2036)
- Figure 3 ESR1 Mutated Metastatic Breast Cancer Epidemiology in the United States (2022-2036)
- Figure 4 ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in the United States (2022-2036)
- Figure 5 ESR1 Mutated Metastatic Breast Cancer Epidemiology in Germany (2022-2036)
- Figure 6 ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in Germany (2022-2036)
- Figure 7 ESR1 Mutated Metastatic Breast Cancer Epidemiology in France (2022-2036)
- Figure 8 ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in France (2022-2036)
- Figure 9 ESR1 Mutated Metastatic Breast Cancer Epidemiology in Italy (2022-2036)
- Figure 10 ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in Italy (2022-2036)
- Figure 11 ESR1 Mutated Metastatic Breast Cancer Epidemiology in Spain (2022-2036)
- Figure 12 ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in Spain (2022-2036)
- Figure 13 ESR1 Mutated Metastatic Breast Cancer Epidemiology in the United Kingdom (2022-2036)
- Figure 14 ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in the United Kingdom (2022-2036)
- Figure 15 ESR1 Mutated Metastatic Breast Cancer Epidemiology in Japan (2022-2036)
- Figure 16 ESR1 Mutated Metastatic Breast Cancer Diagnosed and Treatable Cases in Japan (2022-2036)
The table of contents is not exhaustive; will be provided in the final report
